Relmada Therapeutics, Inc.
RLMDHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Relmada Therapeutics, Inc. focuses on Biotechnology services and products. Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The $453.3M market capitalization puts RLMD squarely in small-cap range for its industry. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
Market Cap
$453.3M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-7.59
EPS (TTM)
$-0.91
EPS (Fwd)
$-0.56
ROE
-25.6%
ROA
-14.4%
Cash
$116.4M
Total Debt
$110,247
Free CF
-$7.7M
52W Change
184.0%
Annual Financials
Cash vs Debt
Where RLMD stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, RLMD finished 22.62% below its 150-day moving average ($5.88) and 16.51% below its 200-day moving average ($5.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RLMD overbought or oversold?
At the August 27, 2026 close, RLMD's RSI(14) was 25.3, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Relmada Therapeutics, Inc. holds $116.4M in cash against $110K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$7.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -25.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RLMD.